<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03944200</url>
  </required_header>
  <id_info>
    <org_study_id>DDS18-034BE</org_study_id>
    <nct_id>NCT03944200</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Bioequivalence Test of DA-1229_01(A) at Fed State</brief_title>
  <official_title>Randomized, Open Label, Single Oral Administration at Fed State, 2 x 2 Crossover Study to Investigate the Bioequivalence Test of DA-1229_01(A)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study demonstrates the bioequivalence of DA-1229_01(A) at Fed State when compared with
      Sugamet sustained-release(SR) Tab 5/1000mg® in healthy adults
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 7, 2019</start_date>
  <completion_date type="Actual">March 25, 2019</completion_date>
  <primary_completion_date type="Actual">March 25, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve(AUCt)</measure>
    <time_frame>Hour -1 ~ Hour 24</time_frame>
    <description>AUCt of metformin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasmaconcentration of drug in plasma(Cmax)</measure>
    <time_frame>Hour -1 ~ Hour 24</time_frame>
    <description>Cmax of metformin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma drug concentration-time curve from time 0 to infinity(AUCinf)</measure>
    <time_frame>Hour -1 ~ Hour 24</time_frame>
    <description>AUCinf of metformin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCt/AUCinf</measure>
    <time_frame>Hour -1 ~ Hour 24</time_frame>
    <description>AUCt/AUCinf of metformin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach the maximum plasma concentration(Tmax)</measure>
    <time_frame>Hour -1 ~ Hour 24</time_frame>
    <description>Tmax of metformin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination rate constant(ramda z)</measure>
    <time_frame>Hour -1 ~ Hour 24</time_frame>
    <description>ramda z of metformin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life(t1/2)</measure>
    <time_frame>Hour -1 ~ Hour 24</time_frame>
    <description>t1/2 of metformin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Type2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Test drug, Reference drug group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar.
The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference drug,Test drug group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Period 1: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar.
The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-1229_01(A), Sugamet SR Tab 5/1000mg®</intervention_name>
    <description>Period 1: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar.
The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar.</description>
    <arm_group_label>Test drug, Reference drug group</arm_group_label>
    <other_name>Test drug, Reference drug group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugamet SR Tab 5/1000mg®, DA-1229_01(A)</intervention_name>
    <description>Period 1: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar.
The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar.</description>
    <arm_group_label>Reference drug,Test drug group</arm_group_label>
    <other_name>Reference drug,Test drug group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients over 19 years of age at the time of health examination

          -  Female patients who were confirmed to be not pregnant at health examination

          -  Patients without a history of mental illness in the past 5 years

        Exclusion Criteria:

          -  Patients who have taken medications which could affect the results of the clinical
             trial in the past 10 days of participating in the clinical trial

          -  Patients with a congestive heart failure which requires medicinal treatment

          -  Patients who have made a whole blood donation in the past 2 months or an apheresis
             donation in the past 2 weeks of participating in the clinical trial

          -  Female patients who are lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sung Dae Kwon, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Metro Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Metro Hospital</name>
      <address>
        <city>Anyang si</city>
        <state>Gyeonggi-do</state>
        <zip>14096</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 1, 2019</study_first_submitted>
  <study_first_submitted_qc>May 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2019</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

